Entacapone
| Entacapone | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 305.29 g/mol [1] |
| Appearance | Crystals from acetic acid + hydrochloric acid [1] |
| Melting point | 162-163 °C [1] |
| Predicted LogP | 2.1 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C14H15N3O5 |
| IUPAC name | (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide |
| SMILES | CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N |
| InChI | InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+ |
| InChIKey | JRURYQJSLYLRLN-BJMVGYQFSA-N |
| CAS number | 130929-57-6 |
| UNII | 4975G9NM6T |
| PubChem CID | 5281081 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 0.4–0.7 hours |
| Metabolism | Hepatic |
| Excretion | Feces (90%), urine (10%) |
| Routes of administration | By mouth |
Entacapone (also known as Comtan, Comtess, Entacapona, Entacaponum, Or-611, (E)-Entacapone, Entacapone teva, Entacapone orion, (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide or (E)-α-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide) is a substance of the aniline class.
Chemistry
Stereochemistry []
Entacapone is achiral.
Druglikeness
Lipinski's rule of five
Entacapone matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- anti-parkinson drugs (N04)
- dopaminergic agents (N04B)
- other dopaminergic agents (N04BX)
- (N04BX02)
- entacapone (N04BX02)
MeSH Classification
Mechanism of action []
The mechanism of action of entacapone is believed to be through its ability to inhibit COMT in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome. [1]
Interactions []
Medical side effects []
188 side effects listed on drug labels in SIDER 4.1 (entacapone).
- Dyskinesia
- Movements involuntary
- Nausea
- Diarrhoea
- Loose stools
- Agitation
- Hyperkinesia
- Chromaturia
- Hypokinesia
- Abdominal pain
- Gastrointestinal pain
- Dizziness
- Syncope
- Constipation
- Asthenia
- Fatigue
- Pain
- Confusional state
- Feeling abnormal
- Malaise
- Hallucination
- Nightmare
- Tremor
- Myocardial ischaemia
- Parkinsonism
- Insomnia
- Vomiting
- Headache
- Depression
- Back pain
- Dyspnoea
- Muscle spasms
- Dry mouth
- Myocardial infarction
- Acute coronary syndrome
- Orthostatic hypotension
- Vertigo
- Anxiety
- Dyspepsia
- Flatulence
- Purpura
- Vascular purpura
- Hyperhidrosis
- Sweating
- Somnolence
- Excessive daytime sleepiness
- Bacterial infection
- Dysgeusia
- Gastritis
- Gastrointestinal disorder
- Gastrointestinal symptom NOS
- Rash maculo-papular
- Hepatitis
- Decreased appetite
- Mental disorder
- Colitis
- Urticaria
- Weight decreased
- Albuminuria
- Angina pectoris
- Arthritis
- Ataxia
- Atrial fibrillation
- Coagulopathy
- Bundle branch block
- Bursitis
- Cardiovascular disorder
- Carpal tunnel syndrome
- Chest pain
- Cholangitis
- Cholecystitis
- Cholelithiasis
- Conjunctivitis
- Dysphagia
- Delusion
- Dermatitis
- Rash
- Fungal skin infection
- Diplopia
- Diverticulitis
- Dysuria
- Eczema
- Endocrine disorder
- Toxic epidermal necrolysis
- Epistaxis
- Erythema multiforme
- Oesophagitis
- Congenital eye disorder
- Eye disorder
- Body temperature increased
- Gastroenteritis
- Cardiac disorder
- Cardiac valve disease
- Haematuria
- Haemorrhage
- Haemoglobin
- Herpes simplex
- Hyperbilirubinaemia
- Hypercholesterolaemia
- Hyperglycaemia
- Hypersensitivity
- Hypertension
- Hyperthyroidism
- Hypoaesthesia
- Hypoglycaemia
- Hypotension
- Impulse-control disorder
- Libido increased
- Disturbance in sexual arousal
- Inflammation
- Intermittent claudication
- Pain in extremity
- Leukopenia
- Liver disorder
- Hepatocellular injury
- Foetor hepaticus
- Hypotonia
- Muscle relaxant therapy
- Nervous system disorder
- Nervousness
- Tension
- Neuroleptic malignant syndrome
- Nocturia
- Pathological gambling
- Neuropathy peripheral
- Pharyngitis
- Piloerection
- Pneumonia
- Pruritus
- Rhabdomyolysis
- Salivary hypersecretion
- Convulsion
- Sinusitis
- Skin disorder
- Unspecified disorder of skin and subcutaneous tissue
- Sleep disorder
- Shock
- Loss of consciousness
- Tendonitis
- Thrombocytopenia
- Tooth disorder
- Urinary incontinence
- Urethral disorder
- Urinary tract disorder
- Visual impairment
- Hepatic failure
- Photopsia
- Cataract
- Hepatic function abnormal
- Generalised oedema
- Fluid retention
- Gamma-glutamyltransferase increased
- Muscular weakness
- Paranoia
- Blood alkaline phosphatase increased
- Malnutrition
- Musculoskeletal stiffness
- Stiffness
- Discomfort
- Ill-defined disorder
- Myalgia
- Musculoskeletal discomfort
- Thinking abnormal
- Mental disability
- Cerebration impaired
- Altered state of consciousness
- Abnormal dreams
- Muscle contractions involuntary
- Disturbance in attention
- Faeces discoloured
- Cold sweat
- Hepatic enzyme increased
- Erectile dysfunction
- Hepatobiliary disease
- Change of bowel habit
- Hypersexuality
- Extrasystoles
- Menorrhagia
- Bradycardia
- Injury
- Feeling of body temperature change
- Sexual dysfunction
- Renal pain
- Binge eating
- Menopausal symptoms
- Hot flush
- Fibroadenoma of breast
- Ageusia
Indications
- Parkinson's disease
Legal status []
- Australia: Entacapone is a Schedule 4.
- Brazil: Entacapone is a C1.[3]
- Canada: Entacapone is Prescription only.
- United Kingdom: Entacapone is Prescription only.
- United States: Entacapone is Prescription only.
- European Union: Entacapone is Prescription only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5281081, Entacapone. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5281081
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Entacapone. UNII: 4975G9NM6T. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/4975G9NM6T
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 07:06:57 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 07:06:53 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 07:06:53 |
| gsrs | ok | 2026-11-20 07:06:53 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0012226) | 2026-11-20 07:06:53 |
| kegg | ok | 2026-11-20 07:06:55 |
| pubchem | ok | 2026-11-20 07:06:53 |
| missing (no r/tripreports posts mention it) | 2026-11-20 07:06:53 | |
| sider | ok | 2026-11-20 07:06:53 |
| structure | ok | 2026-11-20 07:06:53 |
| wikipedia | ok | 2026-11-20 07:06:53 |